KARACHI: The Searle Company Limited reported a strong financial performance for the nine months ended March 31, 2026, posting a substantial increase in profitability driven by robust sales growth, improved margins, and significantly lower finance costs.
According to the company’s latest quarterly report, revenue rose 37% year-on-year to Rs. 26.19 billion, compared with Rs. 19.11 billion in the corresponding period last year. The increase was supported by improved product availability, supply chain optimization, and stronger commercial execution across its operations.
Gross profit surged to Rs. 14.43 billion from Rs. 9.61 billion a year earlier, while the gross profit margin improved to 55.1% from 50.3%. The company attributed the stronger margins to strategic pricing adjustments and a favorable product mix.
A key contributor to the earnings improvement was the sharp decline in finance costs, which fell to Rs. 794 million from Rs. 1.72 billion in the same period last year. The reduction followed the settlement of long-term borrowings after the divestment of Searle Pakistan Limited and a decline in benchmark interest rates.
As a result, profit after tax soared to Rs. 2.31 billion, compared with Rs. 269 million recorded during the corresponding period of the previous year, representing a growth of nearly 759%. Earnings per share increased to Rs. 3.93 from Rs. 0.46.
The company also highlighted that the prior-year results were impacted by a one-off impairment loss of Rs. 927 million related to its investment in Searle Pakistan Limited, which further accentuated the year-on-year profit growth.
Looking ahead, Searle expressed confidence in sustaining growth despite ongoing macroeconomic and geopolitical challenges. Management noted that the deregulation of non-essential drug prices, lower interest rates, and a stable exchange rate have improved business predictability and created a more favorable operating environment. The company also cited the recent approval of Denosumab injections by the Drug Regulatory Authority of Pakistan as a significant milestone in its biotechnology portfolio.
Searle said it continues to expand its export footprint across GCC and CIS markets while accelerating digital transformation and sustainability initiatives to enhance operational efficiency and create long-term value for stakeholders.
